Study outcomes
death, primary melanoma
RECURRENCE, METASTASIS
In this study, RFS was separately compared between nivolumab versus placebo and nivolumab versus ipilimumab, and OS was compared between nivolumab versus placebo. The OS comparison between nivolumab versus ipilimumab was not included in the pooled population due to the differences in post-recurrence treatments available in the EORTC 18,071 and Checkmate 238 trials. RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional, or distant metastasis), new primary melanoma (only in CheckMate 238), or death from any cause, whichever occurred first [